Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.
Precision medicine is advancing quicker than ever before in dermatology, and this is of utmost importance for certain complex dermatologic conditions that have proven difficult to understand and manage, said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento.
Transcript
What are your thoughts on the future of therapeutic innovation in dermatology?
I'm just excited about all of the therapies that are coming into dermatology. I think it's a very exciting time, where precision medicine is really starting to happen. We're talking about personalized therapies for certain types of diseases. And I think the immunology is really catching up to what we have in the clinic. And that's been in part due to huge research advances and technological advances where what we couldn't do 5 years ago, even a couple of years ago, we're starting to do today. So, it's a really exciting time.
We're advancing medicine quicker than we have in the past where research was primarily performed or done in silos. Small groups, studying things in their lab with groups of 8 to 20 people, but now we're in big medicine where large companies and organizations are looking at big data. They're coupling with machine learning and artificial intelligence.
So, I think we can start to tackle some of these really complex medical dermatologic conditions, and really start to tease out subtleties that we couldn't look at or understand what we were looking at with a small microscope, but now we've got the power to start to tease out how do the genetics really play a role with environment, etc. So, I just think this is the beginning of medicines that are going to be really targeted and highly effective, and it's just an exciting time to be in medical dermatology right now.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More